A Director at Collegium Pharmaceutical is Exercising Options

By Carrie Williams

Yesterday it was reported that a Director at Collegium Pharmaceutical (COLLResearch Report), Hirsch David, exercised options to sell 22,106 COLL shares at $9.33 a share, for a total transaction value of $257.5K.

This is David’s first transaction since reporting a Buy transaction on MTEM back in September 2018

See today’s analyst top recommended stocks >>

Based on Collegium Pharmaceutical’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $75.04 million and GAAP net loss of $4.71 million. In comparison, last year the company earned revenue of $73.06 million and had a GAAP net loss of $13.06 million. The company has a one-year high of $19.83 and a one-year low of $10.01. Currently, Collegium Pharmaceutical has an average volume of 360.68K.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases.